AstraZeneca said losses on Vaxzevria were the main factor that shaved seven percentage points off its Reported Gross Profit Margin, which fell to 73.5 percent in the first half of the year.
AstraZeneca Lost Money on COVID-19 Vaccine in First Half of 2021